Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domain

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Wang, Jiafu ^a   Meng, Jianghui ^a   Nugent, Marc ^a   Tang, Minhong ^a   Dolly, J Oliver ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BOTULINUM TOXIN A; MEMBRANE PROTEIN; MUTANT PROTEIN; PROTEIN BINDING; RECOMBINANT PROTEIN;

ANIMAL; CELL MEMBRANE; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; NERVE CELL; PARALYSIS; PATHOLOGY; PRIMARY CELL CULTURE; PROTEIN DOMAIN; RAT; SENSORY NERVE CELL; SYNAPSE VESICLE;

ACETYLCHOLINE; ANIMALS; BOTULINUM TOXINS, TYPE A; CELL MEMBRANE; HUMANS; MEMBRANE GLYCOPROTEINS; MUTANT PROTEINS; NEURONS; PARALYSIS; PRIMARY CELL CULTURE; PROTEIN BINDING; PROTEIN DOMAINS; RATS; RECOMBINANT PROTEINS; SENSORY RECEPTOR CELLS; SYNAPTIC VESICLES;

EID: 85015340807     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep44474     Document Type: Article

References (41)

1. Dolly, J. O., Wang, J., Zurawski, T. H. & Meng, J. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators. FEBS J 278, 4454-66 (2011).
2. Dorizas, A., Krueger, N. & Sadick, N. S. Aesthetic uses of the botulinum toxin. Dermatol Clin 32, 23-36 (2014).
3. Hexsel, C., Hexsel, D., Porto, M. D., Schilling, J. & Siega, C. Botulinum toxin type A for aging face and aesthetic uses. Dermatol Ther 24, 54-61 (2011).
4. Gady, J. & Ferneini, E. M. Botulinum toxin A and headache treatment. Conn Med 77, 165-6 (2013).
5. Welch, M. J., Purkiss, J. R. & Foster, K. A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38, 245-58 (2000).
6. Meng, J., Wang, J., Lawrence, G. & Dolly, J. O. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 120, 2864-74 (2007).
7. Durham, P. L., Cady, R. & Cady, R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44, 35-42, discussion 42-3 (2004).
8. Meng, J., Wang, J., Steinhoff, M. & Dolly, J. O. TNFalpha induces co-trafficking of TRPV1/TRPA1 in VAMP1-containing vesicles to the plasmalemma via Munc18-1/syntaxin1/SNAP-25 mediated fusion. Sci Rep 6, 21226, 1-15 (2016).
9. Lacy, D. B., Tepp, W., Cohen, A. C., DasGupta, B. R. & Stevens, R. C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5, 898-902 (1998).
10. Kumaran, D. et al. Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. J Mol Biol 386, 233-45 (2009).
11. Swaminathan, S. & Eswaramoorthy, S. Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 7, 693-9 (2000).
12. Dolly, J. O., Black, J., Williams, R. S. & Melling, J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature 307, 457-60 (1984).
13. Jin, R., Rummel, A., Binz, T. & Brunger, A. T. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444, 1092-5 (2006).
14. Chai, Q. et al. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444, 1096-100 (2006).
15. Black, J. D. & Dolly, J. O. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 103, 521-34 (1986).
16. Meng, J., Wang, J., Lawrence, G. W. & Dolly, J. O. Molecular components required for resting and stimulated endocytosis of botulinum neurotoxins by glutamatergic and peptidergic neurons. FASEB J 27, 3167-80 (2013).
17. Montal, M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 79, 591-617 (2010).
18. Pirazzini, M. et al. Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. Cell Rep 8, 1870-8 (2014).
19. Wang, J. et al. A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J Biol Chem 286, 6375-85 (2011).
20. Jacky, B. P. et al. Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). PLoS Pathog 9, e1003369 (2013).
21. Sun, S. et al. Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly. Cell Host Microbe 10, 237-47 (2011).
22. Benoit, R. M. et al. Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A. Nature 505, 108-11 (2014).
23. Yao, G. et al. N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A. Nat Struct Mol Biol (2016).
24. Lacy, D. B. & Stevens, R. C. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 291, 1091-104 (1999).
25. Muraro, L., Tosatto, S., Motterlini, L., Rossetto, O. & Montecucco, C. The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane. Biochem Biophys Res Commun 380, 76-80 (2009).
26. Zhang, Y. et al. Structural insights into the functional role of the Hcn sub-domain of the receptor-binding domain of the botulinum neurotoxin mosaic serotype C/D. Biochimie 95, 1379-85 (2013).
27. Fernandez-Salas, E. et al. Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc Natl Acad Sci USA 101, 3208-13 (2004).
28. Wang, J. et al. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J Biol Chem 283, 16993-7002 (2008).
29. Aoki, K. R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon 39, 1815-20 (2001).
30. Dong, M. et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 312, 592-6 (2006).
31. Dong, M. et al. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 19, 5226-37 (2008).
32. Meng, J. et al. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci 29, 4981-92 (2009).
33. Williams, R. S., Tse, C. K., Dolly, J. O., Hambleton, P. & Melling, J. Radioiodination of botulinum neurotoxin type A with retention of biological activity and its binding to brain synaptosomes. Eur J Biochem 131, 437-45 (1983).
34. Chaddock, J. A. et al. A conjugate composed of nerve growth factor coupled to a non-toxic derivative of Clostridium botulinum neurotoxin type A can inhibit neurotransmitter release in vitro. Growth Factors 18, 147-55 (2000).
35. Duggan, M. J. et al. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem 277, 34846-52 (2002).
36. Arsenault, J. et al. Stapling of the botulinum type A protease to growth factors and neuropeptides allows selective targeting of neuroendocrine cells. J Neurochem 126, 223-33 (2013).
37. Masuyer, G., Chaddock, J. A., Foster, K. A. & Acharya, K. R. Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol Toxicol 54, 27-51 (2014).
38. Somm, E. et al. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J Clin Invest 122, 3295-306 (2012).
39. Dressler, D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol 48, 26-9 (2002).
40. Lange, O. et al. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32, 213-8 (2009).
41. Studier, F. W. Protein production by auto-induction in high density shaking cultures. Protein Expr Purif 41, 207-34 (2005).